New persistent opioid use following surgery among opioid-naïve patients in the USA: a systematic review and meta-analysis of observational studies

BACKGROUND: New persistent opioid use (NPOU) after surgery is a serious surgical complication associated with increased risk of opioid abuse, mortality, morbidity, and greater healthcare resource utilization. OBJECTIVE: This meta-analysis aimed to estimate the pooled incidence of NPOU following surgery in the USA and examine its association with selected risk factors, patient characteristics, and study characteristics. EVIDENCE REVIEW: PubMed and Embase were searched on March 1, 2024, to identify observational studies published between January 1, 2013, and March 1, 2024, that reported the incidence of NPOU among adult patients newly prescribed opioids for postsurgical pain. Study quality was assessed using the Newcastle-Ottawa Scale for cohort studies. Pooled incidence estimates of NPOU were generated using random-effects models overall and within subgroups stratified by surgery type, payer coverage, exclusion of subsequent analgesia/surgery, and NPOU definitions. Meta-regression analyses were conducted to explore associations between NPOU and select patient attributes. The protocol was registered in PROSPERO (CRD42023446403). FINDINGS: =100%) and a 95% prediction interval of 1.34% to 17.02%. Metaregression analyses indicated that the pooled estimate was not significantly associated with study sample size, racial distribution, proportion of male patients, or mean age. Estimates of NPOU did not differ significantly by surgery type (p=0.4912), payer coverage (p=0.0697), or subsequent analgesia/surgery (p=0.6335). However, incidence estimates were significantly higher in the 35 studies defining NPOU as opioid use within 90-180 days after surgery (8.29%, p<0.0001) compared with eight studies applying a more stringent definition of NPOU requiring evidence of opioid use over a 180-day postoperative period (2.89%). CONCLUSIONS: This large meta-analysis indicates that NPOU is a common but highly variable outcome among opioid-naive surgical patients in the USA who are prescribed opioids for acute pain. Given the high volume of surgeries performed annually, these findings suggest millions of patients may be at risk for persistent opioid use and related adverse outcomes. However, results should be interpreted cautiously, given the substantial between-study heterogeneity and the inherent limitations of the observational studies included. These findings highlight an urgent need for effective non-opioid pain management strategies and policies to improve access to safer alternatives.

Authors

Institutions

Publication Details

Journal
Regional Anesthesia & Pain Medicine
Published
2026-06-26
DOI
https://doi.org/10.1136/rapm-2025-107296
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

New persistent opioid use following surgery among opioid-naïve patients in the USA: a systematic review and meta-analysis of observational studies

Konrad Pisarczyk, Stephan Frangakis, A.M. Menzie, Scott J. Keating et al.
Regional Anesthesia & Pain Medicine
Opioid Use Disorder Treatment
article

New persistent opioid use following surgery among opioid-naïve patients in the USA: a systematic review and meta-analysis of observational studies

Konrad Pisarczyk, Stephan Frangakis, A.M. Menzie, Scott J. Keating, Jan Tuzil
article en

Abstract

BACKGROUND: New persistent opioid use (NPOU) after surgery is a serious surgical complication associated with increased risk of opioid abuse, mortality, morbidity, and greater healthcare resource utilization. OBJECTIVE: This meta-analysis aimed to estimate the pooled incidence of NPOU following surgery in the USA and examine its association with selected risk factors, patient characteristics, and study characteristics. EVIDENCE REVIEW: PubMed and Embase were searched on March 1, 2024, to identify observational studies published between January 1, 2013, and March 1, 2024, that reported the incidence of NPOU among adult patients newly prescribed opioids for postsurgical pain. Study quality was assessed using the Newcastle-Ottawa Scale for cohort studies. Pooled incidence estimates of NPOU were generated using random-effects models overall and within subgroups stratified by surgery type, payer coverage, exclusion of subsequent analgesia/surgery, and NPOU definitions. Meta-regression analyses were conducted to explore associations between NPOU and select patient attributes. The protocol was registered in PROSPERO (CRD42023446403). FINDINGS: =100%) and a 95% prediction interval of 1.34% to 17.02%. Metaregression analyses indicated that the pooled estimate was not significantly associated with study sample size, racial distribution, proportion of male patients, or mean age. Estimates of NPOU did not differ significantly by surgery type (p=0.4912), payer coverage (p=0.0697), or subsequent analgesia/surgery (p=0.6335). However, incidence estimates were significantly higher in the 35 studies defining NPOU as opioid use within 90-180 days after surgery (8.29%, p<0.0001) compared with eight studies applying a more stringent definition of NPOU requiring evidence of opioid use over a 180-day postoperative period (2.89%). CONCLUSIONS: This large meta-analysis indicates that NPOU is a common but highly variable outcome among opioid-naive surgical patients in the USA who are prescribed opioids for acute pain. Given the high volume of surgeries performed annually, these findings suggest millions of patients may be at risk for persistent opioid use and related adverse outcomes. However, results should be interpreted cautiously, given the substantial between-study heterogeneity and the inherent limitations of the observational studies included. These findings highlight an urgent need for effective non-opioid pain management strategies and policies to improve access to safer alternatives.

Regional Anesthesia & Pain Medicine
University of Michigan (US), Vertex Pharmaceuticals (United States) (US)
Vertex Pharmaceuticals
Openalex Percentile: Top 6%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.